bezafibrate has been researched along with Insulin Sensitivity in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.50) | 18.7374 |
| 1990's | 8 (20.00) | 18.2507 |
| 2000's | 20 (50.00) | 29.6817 |
| 2010's | 11 (27.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, M; Fukuda, N; Haketa, A; Hatanaka, Y; Kobayashi, H; Nakamura, Y; Soma, M; Tanaka, S; Tsunemi, A; Ueno, T | 1 |
| Goto, T; Hirata, M; Inoue, H; Kamakari, K; Kawada, T; Nakata, R; Shibata, D; Suzuki, H; Takahashi, H; Takahashi, N; Yamazaki, Y | 1 |
| Adamski, J; Aichler, M; Baumann, M; Beckers, J; Dubois, G; Feuchtinger, A; Franko, A; Fuchs, H; Gradinger, D; Hrabě de Angelis, M; Huypens, P; Irmler, M; Massinger, R; Neff, F; Neschen, S; Peter, A; Prehn, C; Prokisch, H; Przemeck, GK; Rathkolb, B; Repp, B; Rozman, J; Sanchez-Lasheras, C; Schommers, P; Schubert, M; Stöhr, O; Walch, AK; Wiesner, RJ; Wolf, E | 1 |
| Aichler, M; Brachthäuser, L; Feuchtinger, A; Franko, A; Fuchs, H; Häring, HU; Hrabě de Angelis, M; Kovarova, M; Neff, F; Neschen, S; Peter, A; Rathkolb, B; Rozman, J; Wolf, E | 1 |
| Goldbourt, U; Lutski, M; Tanne, D; Weinstein, G | 1 |
| Adler, Y; Behar, S; Boyko, V; Fisman, EZ; Goldberg, I; Inoue, T; Matas, Z; Node, K; Schwammenthal, E; Tenenbaum, A | 1 |
| Balasubramanian, R; Cobelli, C; Dalla Man, C; English, PT; Firbank, MJ; Gerrard, J; Lane, A; Taylor, R | 1 |
| Gdula-Dymek, A; Krysiak, R; Okopien, B | 2 |
| Goto, T; Hirai, S; Inoue, H; Kawada, T; Kim, YI; Lee, JY; Takahashi, N; Teraminami, A; Uemura, T | 1 |
| Fisman, EZ; Tenenbaum, A | 1 |
| Hayashi, S; Iwashima, Y; Kawano, Y; Nakamura, S; Ohta, Y; Yoshihara, F | 1 |
| Mori, Y | 1 |
| Aoki, Y | 1 |
| Bamberg, K; Camejo, G; Dahllöf, B; Kjellstedt, A; Ljung, B; Oakes, ND; Ostling, J; Svensson, L | 1 |
| Kotake, H | 1 |
| Bratt, G; Nyström, T; Sjöholm, A | 1 |
| Nakagawa, M; Onishi, T; Saibara, T; Saika, K; Shizuta, Y; Sugiura, T; Takeda, K; Toda, K | 1 |
| Fujioka, Y; Kim, JI; Saito, K; Tsujino, T; Yokoyama, M | 1 |
| de Man, FH; Hattori, H; Jonkers, IJ; Scheek, LM; Smelt, AH; van der Laarse, A; van Gent, T; van Tol, A | 1 |
| Jia, D; Otani, M; Otsuki, M; Yamamoto, M | 1 |
| Carmody, MW; Davidoff, AJ; Davidson, MB; Hintz, KK; Mason, MM; Podolin, DA; Ren, J; Wold, LE | 1 |
| Kiniwa, M; Matsuura, N; Ohmori, K; Yamada, H; Yamamoto, A; Yasuda, A | 1 |
| Brand, CL; Pickavance, LC; Wassermann, K; Wilding, JP | 1 |
| Boverhof, R; Jonkers, IJ; Kuipers, F; Masclee, AA; Princen, HM; Romijn, JA; Smelt, AH; Stellaard, F | 1 |
| Behar, S; Benderly, M; Boyko, V; Fisman, EZ; Haim, M; Matas, Z; Motro, M; Tanne, D; Tenenbaum, A | 1 |
| Adler, Y; Behar, S; Boyko, V; Feinberg, M; Fisman, EZ; Lapidot, M; Matas, Z; Motro, M; Schwammenthal, E; Tanne, D; Tenenbaum, A; Tenenbaum, H | 1 |
| Arai, N; Ebihara, K; Hosoda, K; Inada, Y; Ishii, T; Maruyama, K; Masuzaki, H; Nakano, S; Nakao, K; Shibata, N; Tanaka, T; Yamazaki, Y; Yasue, S | 1 |
| Inokuchi, T; Ka, T; Kobayashi, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T | 1 |
| Hübinger, A; Müller, HJ; Vogelberg, KH | 1 |
| de Faire, U; Ericsson, CG; Hamsten, A; Nilsson, J | 1 |
| Hibino, M; Ito, T; Kawakami, K; Matsui, H; Okumura, K; Toki, Y | 1 |
| Barradell, LB; Goa, KL; Plosker, GL | 1 |
| Joffe, BI; Kedda, MA; Panz, VR; Raal, FJ; Wing, JR | 1 |
| Båvenholm, P; de Faire, U; Ericsson, CG; Godsland, I; Hamsten, A; Jovinge, S; Nilsson, J; Proudler, A; Tornvall, P | 1 |
| Adzet, T; Alegret, M; Cabrero, A; Laguna, JC; Llaverías, G; Roglans, N; Sánchez, R; Vázquez, M | 1 |
| Anyaoku, V; Diamond, JR; Elkeles, RS; Hughes, C; Richmond, W | 1 |
| Doi, K; Fukunaga, A; Fukushima, M; Kishimoto, H; Kitatani, N; Matsuura, T; Nagasaka, S; Nagata, I; Nakai, Y; Nakaishi, S; Okumura, T; Sakai, M; Taniguchi, A; Tokuyama, K; Yamashita, Y | 1 |
| Jonkers, IJ; Mohrschladt, MF; Smelt, AH; van der Laarse, A; Westendorp, RG | 1 |
| Karhapää, P; Laakso, M; Uusitupa, M; Voutilainen, E | 1 |
5 review(s) available for bezafibrate and Insulin Sensitivity
| Article | Year |
|---|---|
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Topics: Animals; Bezafibrate; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Insulin Resistance; Lipids; Peroxisome Proliferator-Activated Receptors; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
[Uncoupling protein-3 in skeletal muscle].
Topics: Animals; Bezafibrate; Carrier Proteins; Diabetes Mellitus; Energy Metabolism; Glucose; Humans; Hypolipidemic Agents; Insulin Resistance; Ion Channels; Lipid Metabolism; Mitochondrial Proteins; Muscle, Skeletal; Obesity; Uncoupling Protein 3 | 2002 |
[Glucose intolerance in liver diseases].
Topics: Bezafibrate; Diabetes Mellitus; Glucose Intolerance; Humans; Hypolipidemic Agents; Insulin Resistance; Liver Diseases | 2002 |
[Syndrome X].
Topics: Animals; Bezafibrate; Biguanides; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Leptin; Life Style; Metabolic Syndrome; Pioglitazone; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2002 |
Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
Topics: Angina Pectoris; Apolipoproteins; Apolipoproteins A; Bezafibrate; Diabetes Complications; Drug Tolerance; Fibrinogen; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Lipoproteins; Male; Myocardial Infarction | 1996 |
15 trial(s) available for bezafibrate and Insulin Sensitivity
| Article | Year |
|---|---|
Insulin Resistance and Future Cognitive Performance and Cognitive Decline in Elderly Patients with Cardiovascular Disease.
Topics: Aged; Bezafibrate; Cardiovascular Diseases; Cognition; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Insulin Resistance; Linear Models; Longitudinal Studies; Male; Middle Aged | 2017 |
Monocyte-suppressing effect of bezafibrate but not omega-3 fatty acids in patients with isolated hypertriglyceridaemia.
Topics: Bezafibrate; C-Reactive Protein; Cytokines; Fatty Acids, Omega-3; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Inflammation; Insulin Resistance; Male; Middle Aged; Monocytes | 2011 |
Hemostatic effects of bezafibrate and ω-3 fatty acids in isolated hypertriglyceridemic patients.
Topics: Bezafibrate; Blood Glucose; Fatty Acids, Omega-3; Female; Hemostasis; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Insulin Resistance; Lipid Metabolism; Male; Middle Aged | 2011 |
Effect of bezafibrate on office, home and ambulatory blood pressure in hypertensive patients with dyslipidemia.
Topics: Aged; Antihypertensive Agents; Bezafibrate; Biomarkers; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Dyslipidemias; Female; Humans; Hypertension; Hypolipidemic Agents; Insulin; Insulin Resistance; Japan; Lipids; Male; Middle Aged; Office Visits; Predictive Value of Tests; Treatment Outcome | 2013 |
Bezafibrate improves hypertension and insulin sensitivity in humans.
Topics: Adult; Apolipoproteins; Bezafibrate; Blood Glucose; Blood Pressure; Body Mass Index; Cell Membrane; Erythrocyte Membrane; Fatty Acids; Heart Rate; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipids; Male | 2003 |
Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy.
Topics: Adrenergic beta-Antagonists; Adult; Bezafibrate; Blood Glucose; Carrier Proteins; Cholesterol Esters; Cholesterol, HDL; Cross-Over Studies; Data Interpretation, Statistical; Double-Blind Method; Female; Humans; Hypertriglyceridemia; Insulin; Insulin Resistance; Linear Models; Male; Membrane Proteins; Middle Aged; Molecular Weight; Phospholipid Transfer Proteins | 2003 |
Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia.
Topics: Bezafibrate; Bile Acids and Salts; Blood Glucose; Body Mass Index; Chenodeoxycholic Acid; Cholesterol; Cholic Acid; Clofibric Acid; Cross-Over Studies; Fasting; Fish Oils; Gallstones; Humans; Hypertriglyceridemia; Insulin; Insulin Resistance; Lipids; Male; Middle Aged; Triglycerides | 2006 |
Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes.
Topics: Aged; Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Female; Follow-Up Studies; Homeostasis; Humans; Hypolipidemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Lipids; Male; Middle Aged; Placebos | 2007 |
Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH.
Topics: Bezafibrate; Biomarkers; Body Mass Index; Fenofibrate; Gout; Humans; Hydrogen-Ion Concentration; Hypolipidemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Nephrolithiasis; PPAR alpha; Regression Analysis; Triglycerides; Uric Acid | 2007 |
[The somatostatin infusion test for the evaluation of glucose utilization in bezafibrate medication].
Topics: Adult; Bezafibrate; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Insulin Resistance; Somatostatin; Time Factors | 1984 |
Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
Topics: Adult; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Double-Blind Method; Humans; Hypolipidemic Agents; Insulin Resistance; Lipoproteins, HDL; Lipoproteins, LDL; Male; Myocardial Infarction; Patient Compliance; Research Design; Risk Factors; Triglycerides | 1995 |
Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease.
Topics: Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Coronary Artery Disease; Coronary Disease; Glucose; Homeostasis; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Risk Factors; Triglycerides; Tumor Necrosis Factor-alpha | 1998 |
Long term improvement in dyslipidaemia in Type 2 diabetes with bezafibrate is not related to changes in insulin resistance.
Topics: Bezafibrate; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Lipoproteins, HDL; Lipoproteins, LDL; Reference Values; Treatment Outcome | 1999 |
Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients.
Topics: Adult; Aged; Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Japan; Male; Middle Aged | 2001 |
Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.
Topics: Bezafibrate; Blood Glucose; C-Reactive Protein; Cross-Over Studies; Double-Blind Method; Female; Fibrinogen; Humans; Hypertriglyceridemia; Hypolipidemic Agents; In Vitro Techniques; Inflammation; Inflammation Mediators; Insulin; Insulin Resistance; Interleukin-6; Lipids; Male; Middle Aged; Tumor Necrosis Factor-alpha | 2002 |
20 other study(ies) available for bezafibrate and Insulin Sensitivity
| Article | Year |
|---|---|
Lipoprotein Lipase Deficiency Arising in Type V Dyslipidemia.
Topics: Adult; Age of Onset; Bezafibrate; Diabetes Complications; Ezetimibe; Genetic Variation; Heterozygote; Humans; Hyperlipoproteinemia Type I; Hypertriglyceridemia; Hypolipidemic Agents; Insulin Resistance; Lipoprotein Lipase; Male | 2019 |
Metabolomics reveal 1-palmitoyl lysophosphatidylcholine production by peroxisome proliferator-activated receptor α.
Topics: 3T3-L1 Cells; Animals; Bezafibrate; Chromatography, High Pressure Liquid; Hepatocytes; Insulin Resistance; Lipid Metabolism; Lysophosphatidylcholines; Male; Metabolomics; Mice; PPAR alpha; RNA, Small Interfering | 2015 |
Bezafibrate Improves Insulin Sensitivity and Metabolic Flexibility in STZ-Induced Diabetic Mice.
Topics: Animals; Bezafibrate; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Experimental; Glucose Tolerance Test; Humans; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Liver; Male; Metabolomics; Mice; Mice, Inbred C57BL; Mitochondria, Liver; Oligonucleotide Array Sequence Analysis; Oxygen Consumption; Peroxisome Proliferator-Activated Receptors | 2016 |
Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.
Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Experimental; Disease Models, Animal; Fatty Liver; Glucose; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Peroxisome Proliferator-Activated Receptors | 2017 |
Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment.
Topics: Aged; Bezafibrate; Coronary Artery Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Peroxisome Proliferator-Activated Receptors; PPAR gamma; Randomized Controlled Trials as Topic; Severity of Illness Index | 2009 |
Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
Topics: Abdominal Muscles; Adult; Aged; Bezafibrate; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Liver; Middle Aged; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Triglycerides | 2010 |
Activation of peroxisome proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Adiposity; Animals; Bezafibrate; Cell Differentiation; Cells, Cultured; Chromatin Immunoprecipitation; Dietary Fats; Fatty Acids; Immunoblotting; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Oxidation-Reduction; PPAR alpha | 2011 |
AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats.
Topics: Alkanesulfonates; Animals; Bezafibrate; Carbohydrate Metabolism; Cinnamates; Diabetes Mellitus; Fatty Acids; Glucose; Humans; Insulin Resistance; Lipid Metabolism; Male; Mass Spectrometry; Mice; Mice, Obese; Molecular Structure; Obesity; Phenylpropionates; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Tumor Cells, Cultured | 2002 |
Bezafibrate-induced improvement in glucose uptake and endothelial function in protease inhibitor-associated insulin resistance.
Topics: Adult; Bezafibrate; Blood Glucose; Brachial Artery; Endothelium, Vascular; HIV-Associated Lipodystrophy Syndrome; Humans; Hypolipidemic Agents; Insulin Resistance; Male; Vasodilation | 2002 |
Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.
Topics: Aging; Animals; Aromatase; Bezafibrate; Blood Glucose; Cholesterol; Estradiol; Glucose Tolerance Test; Insulin; Insulin Resistance; Male; Mice; Mice, Knockout; Models, Animal; Obesity; Pioglitazone; Testosterone; Thiazoles; Thiazolidinediones; Triglycerides | 2003 |
Bezafibrate on lipids and glucose metabolism in obese diabetic Otsuka Long-Evans Tokushima fatty rats.
Topics: Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Eating; Fatty Acids, Nonesterified; Glucose; Glucose Tolerance Test; Hypolipidemic Agents; Immunohistochemistry; Insulin; Insulin Resistance; Islets of Langerhans; Lipid Metabolism; Lipids; Obesity; Pancreas; Rats; Rats, Inbred OLETF; Triglycerides | 2004 |
Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments.
Topics: Animals; Bezafibrate; Diabetes Mellitus, Type 2; Dietary Sucrose; Heart Diseases; Hyperinsulinism; Hypolipidemic Agents; Insulin Resistance; Male; Myocardial Contraction; Myocytes, Cardiac; Physical Conditioning, Animal; Physical Exertion; Rats; Rats, Wistar | 2004 |
Effects of a novel anti-hyperlipidemic agent, S-2E, on blood lipid levels in rats with fructose-induced hypertriglyceridemia.
Topics: Animals; Benzoates; Bezafibrate; Cholesterol; Cholesterol, HDL; Diet; Fructose; Hydroxybenzoate Ethers; Hypertriglyceridemia; Hypolipidemic Agents; Insulin Resistance; Lipid Metabolism; Lipids; Liver; Male; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Triglycerides | 2004 |
The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.
Topics: Adipose Tissue; Animals; Bezafibrate; Body Composition; Body Weight; Diabetes Mellitus; Diet; Energy Metabolism; Glucose Clamp Technique; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Obesity; Organ Size; Oxazines; Pancreas; Phenylpropionates; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Rats, Inbred Strains; Receptors, Cell Surface; Receptors, Leptin; Thiazolidinediones | 2005 |
Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.
Topics: Aged; Bezafibrate; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Female; Humans; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; Randomized Controlled Trials as Topic; Triglycerides | 2006 |
Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3-L1 Cells; Adipocytes; Adiponectin; Adipose Tissue; Animals; Bezafibrate; Diabetes Complications; Diabetes Mellitus; Fatty Acids, Nonesterified; Hyperglycemia; Hypolipidemic Agents; Insulin Resistance; Liver; Male; Mice; Mice, Inbred Strains; Organ Size; Oxidoreductases; Peroxisome Proliferator-Activated Receptors; RNA, Messenger; RNA, Small Interfering; Triglycerides | 2007 |
Improved insulin sensitivity by bezafibrate in rats: relationship to fatty acid composition of skeletal-muscle triglycerides.
Topics: Animals; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Delta-5 Fatty Acid Desaturase; Dietary Carbohydrates; Dietary Fats; Fatty Acid Desaturases; Fatty Acids; Fatty Acids, Nonesterified; Fructose; Insulin; Insulin Resistance; Male; Muscle, Skeletal; Phospholipids; Rats; Rats, Sprague-Dawley; Triglycerides | 1997 |
Improved glucose tolerance after effective lipid-lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: a putative role for Randle's cycle in its pathogenesis?
Topics: Adolescent; Bezafibrate; Blood Glucose; Diabetes Mellitus, Lipoatrophic; Fatty Acids, Nonesterified; Female; Glucose Tolerance Test; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Triglycerides | 1997 |
Uncoupling protein-3 mRNA levels are increased in white adipose tissue and skeletal muscle of bezafibrate-treated rats.
Topics: Adipose Tissue; Animals; Base Sequence; Bezafibrate; Body Weight; Carrier Proteins; Diabetes Mellitus, Type 2; DNA Primers; Hypolipidemic Agents; Insulin Resistance; Ion Channels; Leptin; Male; Mitochondria; Mitochondrial Proteins; Muscle, Skeletal; Organ Size; Proteins; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Uncoupling Protein 3 | 1999 |
Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia.
Topics: Bezafibrate; Calorimetry, Indirect; Delayed-Action Preparations; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hyperlipidemia, Familial Combined; Insulin Resistance; Liver; Male; Middle Aged; Triglycerides | 1992 |